Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

NCT03702179 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT03702179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03702179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2018
Completion date
August 16, 2022
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

invasive bladder cancer